Pre-made Dacetuzumab benchmark antibody ( Whole mAb, anti-CD40 therapeutic antibody, Anti-p50/Bp50/CDW40/TNFRSF5 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-128

Pre-Made Dacetuzumab biosimilar, Whole mAb, Anti-CD40 Antibody: Anti-p50/Bp50/CDW40/TNFRSF5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Dacetuzumab (also known as SGN-40 or huS2C6) is a humanized monoclonal antibody being developed for the treatment of CD40-positive cancers like non-Hodgkin's lymphoma and hematological malignancies.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-128-1mg 1mg 3090 Inquiry Inquiry

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Dacetuzumab biosimilar, Whole mAb, Anti-CD40 Antibody: Anti-p50/Bp50/CDW40/TNFRSF5 therapeutic antibody
INN Name Dacetuzumab
TargetCD40
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2007
Year Recommended2008
CompaniesSeattle Genetics
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedChronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Multiple myeloma;Non-Hodgkin's lymphoma
Development Techna